key: cord-0888079-u258jw0t
authors: Mayanskiy, Nikolay; Luchkina, Polina; Fedorova, Natalia; Lebedin, Yuri; Ponomareva, Natalia
title: Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients
date: 2021-05-18
journal: Leukemia
DOI: 10.1038/s41375-021-01288-0
sha: 20a5e34f3daab13b0dc069401aa9a136e18acfd9
doc_id: 888079
cord_uid: u258jw0t

nan

28 or 29, 2020. Clinical characteristics are shown in Supplementary Table 1 . The majority of patients demonstrated a mild course of COVID-19 with minimal symptoms. Fever was the most common symptom (14/18); anosmia was reported in 4 (22%) patients. Among 12 patients with a lung CT scan performed, in 6 (50%) no lung involvement was found, in 5 (42%) and 1 (8%) lung involvement of CT grade 1 and 2, respectively, was observed (Supplementary Table 1 ).

In total, we collected 113 residual serum specimens from these patients at different time points and detected serum IgM and IgG against the receptor binding domain (RBD) of the S protein (anti-RBD) and the nucleocapsid protein (anti-N) of SARS-CoV-2 ( Fig. 1A Anti-RBD IgG were the most prevalent antibodies detected in 92% patients by week 6 (Fig. 1A , Supplementary Table 2 ). The highest seroprevalence rate for anti-N IgG was around 70-75%. The rate of anti-RBD IgM was 23-44% by weeks 3 to 4; IgM antibodies vanished at the end of the 9-week follow-up period. Anti-N IgM were detected in two patients (in one patient simultaneously with anti-RBD IgM).

To assess the anti-SARS-CoV-2 antibody profile distribution at the specimen level, we selected virus-specific Ig-positive serum specimens, where both anti-SARS-CoV-2 IgG and IgM antibodies were measured (n = 85). The majority of specimens (71/85; 84%) contained anti-RBD IgG antibodies alone or in combination with anti-N IgG and/or anti-RBD IgM (Supplementary Table 3 ). In 8/85 (9%) specimens, exclusively anti-N IgG was present. Anti-SARS-CoV-2 IgM was detected in 15/85 (18%) virusspecific Ig-positive specimens; all IgM-positive specimens concurrently contained virus-specific IgG antibodies, except one specimen, where only anti-RBD IgM was detected (Supplementary Table 3 ). Next, we analyzed the magnitude of the IgG antibody response using positivity index (PI) values calculated as the ratio between the specimen and the internal cut-off control optical density, which reflected the antibody level (Fig. 1B,  C) . The level of anti-RBD IgG increased up to a median PI value of 3.27 (IQR 3.04) over weeks [3] [4] , and plateaued at a median PI value around 2.0 by week 6 persisting at that level at least until week 9. At the last flow-up time point (week 18), a median PI value declined to 0.95 (IQR 0.64). The level of anti-N IgG demonstrated a slightly different dynamics with a delayed peak PI value of 1.79 (IQR 1.96) by week 6 (Fig. 1B, C) .

Our findings addressed several important issues. We demonstrated that pediatric patients with hematological neoplasia or solid tumors responded to a SARS-CoV-2 infection producing antibodies of different isotypes against the RBD and N target antigens of the virus. Interestingly, a report has suggested that children may have a distinct antibody response to SARS-CoV-2 compared to adults and generate predominantly anti-spike antibodies, but not anti-N [3] , which we did not observe in the present study. All examined patients demonstrated seroconversion, which persisted in more than a half of patients for at least 18 weeks. The functionality and longevity of the immune response against SARS-CoV-2 in such patients warrant further elaboration. As was mentioned above, adult acute leukemia patients were capable of developing neutralizing anti-SARS-CoV-2 antibodies [2] . In our study, the majority Table 2. of patients demonstrated the presence of anti-spike (anti-RBD) antibodies, which titers appear to closely correlate with the neutralizing capacity [4] . Moreover, a recent metaanalysis has demonstrated that pediatric patients with COVID-19 suffering from hematological neoplasia or solid tumors were not at an increased risk of unfavorable outcomes [5] . Taken together, these data may indicate that pediatric patients with malignancies are unlikely to be more vulnerable to COVID-19 comparing to other children, as had been noticed earlier [6] . However, the situation may be different in hospitalized adults with hematological neoplasia and accompanying COVID-19, who have demonstrated more severe disease and a higher case fatality rate [7] .

Our results indicated that although the majority of specimens contained anti-RBD IgG antibodies, among the anti-SARS-CoV-2 IgG-positive specimens there were 13% where exclusively anti-N IgG occurred. This finding suggested that the detection of antibodies to both targets would increase the sensitivity of serological analysis.

In conclusion, further study of the immune response to SARS-CoV-2 infection in children with cancer is critical for providing medical care and implementing optimal protection in this patient group in the context of the COVID-19 pandemic [8] .

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

SARS-CoV-2 antibody responses in patients with acute leukaemia

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis

COVID-19 in children with cancer in New York city

COVID-19 in persons with haematological cancers

EHA Infectious Disease Scientific Working Group, Hirsch HH. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.